GNH USA

Europe — EMA

Normosang (Human Hemin)

GNH USA supplies Normosang (Human Hemin), a heme (hemin) preparation for acute intermittent porphyria and related attacks. Request a quote for global supply.

Human Hemin

Request sourcing

1
Pack/s

What is Human Hemin?

Human Hemin, the active ingredient in Normosang, is a heme (hemin) preparation presented as a lyophilized powder for solution for injection for intravenous use. It is employed to treat acute intermittent porphyria and other acute hepatic porphyria attacks in affected patients.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide, ensuring quality‑controlled delivery and regulatory compliance. Our distribution network covers major medical centers across Europe, Asia and the Americas, facilitating timely access to this essential therapy.

What is Human Hemin used for?

Normosang is used to manage acute hepatic porphyria attacks by providing exogenous heme. - Acute intermittent porphyria: reduces neurotoxic precursor accumulation and alleviates acute attack symptoms. - Variegate porphyria: helps control acute episodes by suppressing heme biosynthesis. - Hereditary coproporphyria: mitigates attack severity through feedback inhibition of the pathway.

What are the side effects of Human Hemin?

Human Hemin may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Infusion‑related pain or burning at the injection site. - Nausea or vomiting. - Headache. - Mild fever or chills.

Serious or Rare Side Effects: - Acute hemolytic anemia, particularly in G6PD‑deficient patients. - Severe allergic or anaphylactic reactions. - Thrombophlebitis or venous thrombosis at the infusion site.

What precautions apply to Human Hemin?

Before administering Normosang, several safety considerations should be observed. - Indication verification: confirm the patient is experiencing an acute porphyria attack. - G6PD status: assess for glucose‑6‑phosphate dehydrogenase deficiency to avoid hemolysis. - Renal function: monitor kidney parameters, especially in patients with pre‑existing renal disease. - Concomitant medications: avoid drugs that may exacerbate porphyria or interact with hemin. - Allergic history: check for prior hypersensitivity to hemin or its excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Human Hemin interact with?

Human Hemin can interact with other agents, influencing efficacy or safety.

Major Interactions (Avoid): - Porphyrin‑inducing drugs (e.g., barbiturates, sulfonamides): may counteract hemin’s effect. - Iron‑containing preparations: can increase risk of oxidative stress.

Moderate Interactions (Monitor Closely): - Anticonvulsants such as phenobarbital: may require dose adjustment of hemin. - Hormonal contraceptives: monitor for breakthrough porphyria symptoms. - High‑dose vitamin C: may affect hemin stability; observe infusion site reactions.

Frequently asked questions

What is Normosang used for?+
Normosang is indicated for the treatment of acute attacks of porphyria, primarily acute intermittent porphyria and other acute hepatic porphyria subtypes. By supplying exogenous heme, it helps halt the overproduction of toxic porphyrin precursors that cause severe neurological and abdominal symptoms during an attack.
How does Human Hemin work?+
Human Hemin provides external heme that replenishes intracellular heme stores. The increased heme level feeds back to inhibit aminolevulinic acid synthase (ALAS1), the first enzyme in the heme biosynthetic pathway, thereby reducing the synthesis of aminolevulinic acid and porphobilinogen, the toxic intermediates that trigger porphyria crises.
What determines the usual dose of Normosang?+
The dose of Normosang is individualized and set by the treating physician based on the severity of the porphyria attack, the patient’s weight, renal function, and response to therapy. No fixed dosing regimen is provided here; clinicians calculate the appropriate amount for each case.
Is Normosang safe in pregnancy or breastfeeding?+
Safety data for Human Hemin during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional after careful assessment.
How do I order Normosang from GNH USA?+
To request Normosang, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.
How does Normosang compare with the main alternative drug or class?+
The primary alternative to Normosang is other hemin preparations such as Panhematin. Both deliver exogenous heme and act via the same feedback inhibition of ALAS1. Differences may lie in formulation, packaging, and regulatory approvals, but clinical efficacy and safety profiles are generally comparable when used according to prescribing information.
What are the storage and handling requirements for Normosang?+
Normosang should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The lyophilized powder should be reconstituted with the appropriate diluent immediately before intravenous administration and used within the time frame specified in the product label.
How is Normosang administered?+
Normosang is supplied as a lyophilized powder for solution for injection. After reconstitution, it is administered intravenously, typically as a slow infusion under medical supervision. Administration settings include hospitals or specialized infusion centers where vital signs and infusion reactions can be monitored.
What are the most serious risks associated with Normosang?+
The most serious adverse events include acute hemolytic anemia, especially in patients with glucose‑6‑phosphate dehydrogenase deficiency, severe allergic or anaphylactic reactions, and thrombophlebitis or venous thrombosis at the infusion site. Prompt recognition and management of these events are essential.
Who should not use Normosang?+
Normosang is contraindicated in patients with known hypersensitivity to human hemin or any of its excipients, and it should be avoided in individuals with confirmed G6PD deficiency due to the risk of hemolysis. Use in patients with uncontrolled renal impairment should be carefully evaluated by a physician.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Human Hemin
Route
Intravenous Use
Manufacturer
Recordati Rare Diseases
Origin
EU

Related products

Human Hemin Orphan Europe

Human Hemin Orphan Europe

Human Hemin

Recordati Rare Diseases
EU
Normosang

Normosang

Human Hemin

Recordati Rare Diseases
EU
Normosang

Normosang

Human Hemin

Recordati Rare Diseases
EU
Normosang

Normosang

Human Hemin

Orphan Europe Sarl
EU